Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients.
The lack of IL-12Rbeta1 expression results in a human immunodeficiency and shows the essential role in resistance to infections due to intracellular bacteria. Expand
PU.1 as an essential activator for the expression of gp91(phox) gene in human peripheral neutrophils, monocytes, and B lymphocytes.
- S. Suzuki, A. Kumatori, +6 authors M. Nakamura
- Biology, Medicine
- Proceedings of the National Academy of Sciences…
- 26 May 1998
PU.1 is an essential activator for the expression of gp91(phox) gene in human neutrophils, monocytes, and B lymphocytes and a single-base mutation at position -52 that was identified in a patient with chronic granulomatous disease inhibited the binding of PU.1 to the promoter. Expand
Can serum L-lactate, D-lactate, creatine kinase and I-FABP be used as diagnostic markers in critically ill patients suspected for bowel ischemia
- P. V. D. van der Voort, Berit Westra, +5 authors S. Rijkenberg
- BMC Anesthesiology
- 2 December 2014
Measurement of LDH, CK, and ALAT did not discriminate critically ill patients with proven intestinal ischemia from those with definite diagnosis no-ischemia, however, L-lactate and D-Lactate levels were higher in patients withproven or likely ischemIA and need further study just as I-FABP. Expand
Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
Intravenously administered BsAb in an intrapatient dose escalation study of 3 patients with B cell non-Hodgkin's lymphoma showed limited toxicity (WHO grade II fever and chills) due to tumor necrosis factor-alpha (TNF-alpha) release by T cells, and treatment of patients with a lower tumor load seems to be warranted to evaluate the efficacy of CD3 x CD19 Bs Ab therapy. Expand
Adherence of peritonitis-causing staphylococci to human peritoneal mesothelial cell monolayers.
- I. Haagen, H. J. Heezius, R. Verkooyen, J. Verhoef, H. Verbrugh
- Biology, Medicine
- The Journal of infectious diseases
- 1 February 1990
The adherence of staphylococci to monolayers of human mesothelial cells was studied, and protein A- and teichoic acid-deficient mutants adhered less well than their parent strains, and encapsulated S. epidermidis adhere well to human monothelial Cells. Expand
Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Various types of experiments showed that efficient CD3 x CD19 BsAb-mediated cytolytic capacity was not dependent on expression of either of these surface proteins, which contrasts with normal major histocompatibility complex-restricted antigen-specific cytotoxicity and may be essential for effective in vivo application of this Bs Ab. Expand
No expansion of the pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma.
The B-cell lineage in the BM and peripheral blood of 18 patients with multiple myeloma does not support the concept of a direct involvement (i.e, expansion or activation) of pre-B cells in MM without excluding the possibility of an early oncogenic event at the pre- B cell stage. Expand
Direct sodium measurement prevents underestimation of hyponatremia in critically ill patients
Measurements of electrolytes with a blood gas analyzer is more reliable when a pseudohypernatremia is suspected, as well as in critical ill patients with often a low total protein/albumin concentration, which is currently underestimated. Expand
Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
- I. Haagen, A. Geerars, E. Bast, G. D. de Gast, J. V. D. van de Winkel, W. de Lau
- Chemistry, Medicine
- Therapeutic immunology
- 1 October 1994
Two bispecific monoclonal antibodies with functionally different Fc domains represent alternative strategies in BsAb therapy, the efficacy of which deserves to be compared in vivo. Expand
CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
A bispecific antibody directed to T and B cells (CD3 x CD19 bsAb) was daily infused intravenously in escalating doses in three patients with chemotherapy-resistant non-Hodgkin lymphoma, aimed to activate T cells to kill the malignant B cells. Expand